Progress in the treatment of relapsed or refractory multiple myeloma has been rapid since the introduction of T-cell–redirecting immunotherapies. The identification of B-cell maturation antigen (BCMA) led to the approvals of three bispecific antibodies, two chimeric antigen receptor T-cell (CAR-T) therapies, and an antibody drug conjugate. Talquetamab, a bispecific antibody… Progress in the treatment of relapsed or refractory multiple myeloma has been rapid since the introduction of T-cell–redirecting immunotherapies. The identification of B-cell maturation antigen (BCMA) led to the approvals of three bispecific antibodies, two chimeric antigen receptor T-cell (CAR-T) therapies, and an antibody drug conjugate. Talquetamab, a bispecific antibody…